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Fibrosis is a consequence of injury characterized by
accumulation of excess collagen and other extracel-
lular matrix components, resulting in the destruction
of normal tissue architecture and loss of function.
Sp1 was originally described as a ubiquitous trans-
cription factor. It is involved in the basal expression
of extracellular matrix genes and may, therefore, be
important in ®brotic processes. To evaluate the
effect of Sp1 blockade on the expression of extracel-
lular matrix genes, clones of NIH 3T3 ®broblasts
stably transfected with an anti-sense Sp1 expression
vector. Simultaneously reduced expression of several
extracellular matrix genes as compared with mock-
transfected clones was noted using differential hybri-
dization of cDNA microarrays, without signi®cant
alteration in cell growth. Transfection of human
dermal ®broblasts with several extracellular matrix
gene (COL1A1, COL1A2, COL3A1, COL5A2,
COL7A1, TIMP-1, and decorin) promoter/reporter
constructs demonstrated that anti-sense Sp1-induced
reduction of extracellular matrix gene mRNA
steady-state levels results from transcriptional repres-
sion, consistent with the role of Sp1 as a transcrip-
tion factor. Decoy Sp1 binding oligonucleotides
inhibited COL1A2 promoter activity both in cultured
®broblasts and in vivo, in the skin of transgenic mice,
which have integrated a mouse COL1A2 promoter/
luciferase reporter gene construct. These results indi-
cate that targeting Sp1 ef®ciently blocks extracellular
matrix gene expression, and suggest that such an
approach may represent an interesting therapeutic
alternative toward the treatment of ®brotic disorders.
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p1 was one of the ®rst eukaryotic transcription factors to
be identi®ed and cloned as a factor binding the SV40
early promoter (Dynan and Tjian, 1983). It is the
founding member of a family of proteins with highly
homologous zinc-®nger domains in the C-terminal
region that bind GC or GT boxes, whereas the glutamine-rich
domains in the N-terminus are essential for transcriptional
activation (Kadonaga et al, 1987; Imataka et al, 1992; Kingsley
and Winoto, 1992). Sp1 activates transcription by association with
one of the coactivators associated with the TATA-binding protein
(TBP) in the TFIID complex. In the case of TATA-less promoters,
Sp1 is able to recruit the TATA-binding protein and associated
TFIID, thereby positioning the initiation complex to the correct
start site even in the absence of a TATA box (Pugh and Tjian,
1991; Wu et al, 1994). Other suggested roles for Sp1 in nuclear
processes include remodeling of chromatin structures (Jongstra et al,
1984) and maintenance of methylation-free CpG islands (Brandeis
et al, 1994; MacLeod et al, 1994). Therefore, Sp1 is fundamental for
the establishment of transcriptional competence, in addition to its
role as a transcription factor.
In the majority of promoters containing Sp1-binding sites, Sp1
provides a basal level of transcription (reviewed in Cook et al,
1999). It plays an important part in the expression of numerous
elements of the cell cycle machinery, such as cyclins, Rb-like
proteins, and E2F (Shao and Robbins, 1995; Karlseder et al, 1996;
Lin et al, 1996). Targeted disruption of the mouse Sp1 gene has
shown that Sp1 is critical for normal embryogenesis. Sp1±/±
embryos are severely retarded in their development and display a
marked heterogeneity in their phenotype (Marin et al, 1997).
Interestingly, inactivation of the Sp1 gene is compatible with a
certain degree of cell growth and differentiation, and the expression
of various putative target genes, including that of certain cell cycle-
related genes was not altered in Sp1±/± embryos. Also, CpG islands
remained methylation free and active chromatin was formed at the
globin loci. This may occur possibly because other members of the
Sp1 family partially compensate for the absence of Sp1, thereby
ameliorating the Sp1 knockout (Marin et al, 1997).
Type I collagen and extracellular (ECM) accumulation is one of
the hallmarks of ®brotic conditions. For example, affected skin
areas from patients with systemic sclerosis exhibit abnormal
accumulation of various ECM components, predominantly types
I and III collagens, but also types V and VII, as well as various
proteoglycans (Ishikawa and Horiuchi, 1975; Uitto, 1979; Perlish
et al, 1988). The accumulation of ECM proteins is accompanied by
elevated mRNA steady-state levels of ®brillar collagens (KaÈhaÈri
et al, 1984; Ohta and Uitto, 1987; Scharffetter et al, 1988). It is
generally accepted that transcriptional activation of ECM-related
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genes, and in particular that of collagen genes, is a critical event
underlying the progressive nature of tissue ®brosis, as is observed in
cutaneous lesions from systemic sclerosis or keloid scars (reviewed
in Jimenez and Saitta, 1999; Uitto and Kouba, 2000). It is
reasonable to hypothesize that identifying ef®cient means to
simultaneously reduce ECM-related gene transcription may pro-
vide promising approaches to the therapy of these incurable
diseases.
Several studies have emphasized the importance of Sp1 and
cognate cis-elements in the expression of the genes encoding the a1
and a2 chains of type I collagen in several species (Pogulis and
Freytag, 1993; Tamaki et al, 1995; Chung et al, 1996; Ihn et al,
1996; Miao et al, 1997; Artlett et al, 1998). Also, there are some
indications that Sp1 transcription factor may be involved in the
excessive expression, and resulting deposition, of type I collagen in
®brotic conditions. For example, increased Sp1 binding activity to
the COL1A1 promoter has been observed in ®broblasts derived
from affected skin from patients with systemic sclerosis (Hitraya
et al, 1998). Similarly, ®brogenic stimuli induce Sp1 DNA-binding
activity in Ito cells, a phenomenon that may contribute to the
development of liver ®brosis (Rippe et al, 1995). Also, Sp1 DNA-
binding activity is increased (from 30 min to 12 h post-irradiation)
in a model of g-irradiation-induced lung ®brosis in the rat (Haase
et al, 2000).
The aim of this study was to determine whether Sp1 targeting
could simultaneously block the transcription of several ECM-
related genes, in an attempt to de®ne novel therapeutic approaches
toward treatment of ®brotic disorders. Using a combination of
cDNA array/gene promoter analysis/decoy oligonucleotides tech-
nologies, we provide evidence that interfering with Sp1 expression
or function leads to simultaneous transcriptional inhibition of the
expression of several collagen, proteoglycan, and other ECM-
related genes in ®broblasts. Our study provides a proof of concept
for a gene therapy-based approach against tissue ®brosis, using the
Sp1 transcription factor as a target.
MATERIALS AND METHODS
Cell cultures Human dermal ®broblasts and NIH 3T3 ®broblast
cultures were grown in Dulbecco's modi®ed Eagle's medium
supplemented with 10% heat-inactivated fetal bovine serum, 2 mm
glutamine, and antibiotics (100 units penicillin per ml, 50 mg
streptomycin-G per ml, and 0.25 mg Fungizone per ml). Sp1-de®cient
cells (Dr.osophila melanogaster Schneider L2 cells) were grown in
Schneider's Dr.osophila medium (Life Technologies, Paisley, U.K.).
Plasmid constructs Several ECM gene promoter/reporter gene
constructs were used to examine the part played by Sp1 in their
transcriptional activity. The human COL1A2, COL7A1, and decorin
promoter constructs have been described previously (Mauviel et al, 1995;
Chung et al, 1996; Vindevoghel et al, 1997; Higashi et al, 1998; Kouba
et al, 1999). Human COL1A1 (Li et al, 1995), mouse COL3A1 (Mudryj
and de Crombrugghe, 1988), human COL5A2 (Truter et al, 1992), and
human TIMP-1 (Clark et al, 1997) promoter constructs were kind gifts
from Dr.s S. Jimenez (Thomas Jefferson University, Philadelphia, PA),
B. de Crombrugghe (M.D. Anderson Cancer Center, Houston, TX), F.
Ramirez (Mount Sinai Medical Center, New York, NY), and D.R.
Edwards (University of Calgary, Calgary, Alberta, Canada), respectively.
pPacSp1, an expression vector for Sp1 driven by the actin promoter
(Courey and Tjian, 1988), a kind gift from Dr. R. Tjian (University of
California, Berkeley, CA), was used to express Sp1 in Dr.osophila SL2
cells. Empty pPac0 was used as a control. pRSV/ASSp1 was generated
by cloning a polymerase chain reaction-generated XhoI/HindIII DNA
fragment spanning the region +47 to +181 of the human Sp1 gene
(GenBank no. J03133) in an anti-sense orientation upstream of the Rous
sarcoma virus (RSV) promoter, into pRSV expression vector. Integrity
of the construct was veri®ed by automated sequencing.
Generation of stably transfected ®broblasts NIH 3T3 ®broblast
cultures were transfected with pRSV/ASSp1 together with pCMVneo, a
plasmid that expresses the neomycin-resistance gene under the control of
the cytomegalovirus promoter, at a 10:1 ratio using the calcium
phosphate/DNA coprecipitation method. Four days after transfection,
(Sigma, St Louis, MO), 0.8 mg Geneticin per ml, was added to the
culture medium to allow the selection of transfected cells. After 15±20 d,
several clones were isolated and propagated in maintenance medium
containing 0.4 mg per ml of Geneticin.
Electrophoresis mobility shift assays A 22-mer consensus Sp1
oligonucleotide 5¢-ATTCGATCGGGGCGGGGCGAGC-3¢ was used as
a probe to determine Sp1/DNA interactions. For supershift experiments,
nuclear extracts (5 mg) were incubated for 2 h on ice with an anti-Sp1
antibody (Santa Cruz Biotechnologies, Santa Cruz, CA) prior to the
binding reactions. Binding mixtures were separated electrophoretically on
native 4% acrylamide gels, as described previously (Vindevoghel et al,
1997).
Western blot analysis Whole cell lysates were prepared by ®rst
washing cells twice in 1 3 phosphate-buffered saline, and then scraping
directly into Laemmli buffer (62.5 mm Tris±HCl, pH 6.8, 2% sodium
dodecyl sulfate, 10% glycerol, 0.5 mm phenylmethylsulfonyl ¯uoride).
Protein concentration of lysates was assayed with the BIO-RAD
(Marnes-Coquette, France) protein reagent, and 20±60 mg of protein was
denatured by heating at 95°C for 3 min prior to resolution by sodium
dodecyl sulfate±polyacrylamide gel electrophoresis. After electrophoresis,
proteins were transferred to Hybond ECL nitrocellulose ®lters
(Amersham, Piscataway, NJ), immunoblotted with a rabbit anti-Sp1
antibody (1:1000, Santa Cruz Biotechnologies), and revealed using a
chemiluminescence detection system (ECL+, Amersham).
Transient cell transfection and CAT assays Transient cell
transfections were performed with the calcium phosphate/DNA copre-
cipitation procedure. CAT activity was measured using
[14C]chloramphenicol as substrate (Gorman et al, 1982) followed by
thin layer chromatography and quantitation with a phosphorimager.
Differential hybridization of Atlas human cDNA expression
arrays Total RNA was obtained using an RNeasy kit (Qiagen GmbH,
Hilden, Germany). DNAase I treatment was performed on the RNA
samples directly on the spin columns to avoid genomic DNA
contamination. Radioactive cDNA synthesis was carried out as described
in the Atlas cDNA expression arrays user manual (Clontech, San Diego,
CA). Equal amounts of radiolabeled cDNAs (107 cpm) from clones
transfected with either pRSV/ASSp1 or empty pRSV were hybridized in
parallel to two Atlas cDNA expression arrays for 18 h at 68°C. The
mouse-speci®c Atlas expression arrays (Clontech no. 7741-1) were
washed four times in 2 3 sodium citrate/chloride buffer and 1% sodium
dodecyl sulfate for 30 min at 68°C and twice in 0.1 3 sodium citrate/
chloride buffer and 0.5% sodium dodecyl sulfate at 68°C, according to
the manufacturer's protocol. Atlas human cell interaction arrays
(Clontech no. 7746-1) hybridized with mouse RNA-derived
radiolabeled cDNAs were washed in the same solutions as above, but at
a temperature of 52°C, which was determined to provide the best
signal/background ratio. Membranes were then exposed to Kodak
phosphor screens for 3 d. Hybridization signals were quantitated with a
Storm 840 phosphorimager using the ImageQuant software (Amersham
Pharmacia Biotech), and normalized against glyceraldehyde-3-phosphate
dehydrogenase mRNA levels in the same samples. Signi®cance of
inhibition of gene expression was set arbitrarily to 2-fold.
Decoy oligonucleotides In some in vitro experiments decoy double-
stranded oligonucleotides were used in an attempt to interfere with Sp1
binding to its cognate cis-elements within the COL1A2 promoter.
Speci®cally, a 22-mer consensus Sp1 oligonucleotide, 5¢-ATTCGATC-
GGGGCGGGGCGAGC-3¢, was added to the culture medium of
dermal ®broblasts transfected with ± 3500COL1A2/CAT. A mutant
oligonucleotide, mSp1, 5¢-ATTCGATCGTAGCGATGCGAGC-3¢,
was used as a control. Twenty-four hours later, CAT activity,
representing promoter activity, was determined.
Treatment of transgenic mice To test the effects of decoy Sp1
oligonucleotides on COL1A2 promoter activity in vivo, 15 mg of either
Sp1 or mSp1 oligonucleotides in 25 ml of H2O, were injected
intradermally into 15 d old transgenic mice harboring the luciferase gene
under the control of 17 kb of the mouse COL1A2 promoter (Bou-
Gharios et al, 1996). After 24 h, the animals were killed and a » 1 cm2
area of the skin covering the site of injections was removed and
homogenized with a tissue grinder into luciferase reporter lysis buffer
(Promega Corp., Madison, WI). Luciferase activity using identical
amounts of extracted proteins was determined with a commercial assay
kit (Promega).
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RESULTS
Stably transfected pRSV/ASSp1 ef®ciently reduces Sp1
expression in NIH 3T3 ®broblasts Several clones transfected
with the pRSV/ASSp1 anti-sense Sp1 expression vector were
isolated and tested by electrophoresis mobility shift assay for their
Sp1 DNA-binding activity. As shown in Fig 1(A), amounts of
DNA/protein complexes (arrow) in nuclear extracts prepared from
con¯uent plates from the different clones tested (A±E, lanes 2±6)
varied signi®cantly, although they were always lower than the
binding activity observed in a control clone (0) transfected with
empty pRSV (lane 1). Phosphorimager quantitation of the
radioactivity present in the various complexes indicated that
clone B contains the least DNA-binding activity (about 2% of
the radioactivity present in complexes formed with control nuclear
extracts). An anti-Sp1 antibody ef®ciently supershifted the complex
observed in the control extracts (Fig 1B, lanes 1 and 2), as well as
the residual Sp1/DNA complexes observed in clone B (lanes 3 and
4), attesting for their identity as Sp1/DNA complexes, as expected
from previous work from our laboratory (Vindevoghel et al, 1997).
Western blot analysis of whole cell extracts indicated that the
decreased Sp1 DNA-binding activity observed in clone B was due
to a reduced Sp1 content (Fig 1C), further attesting the ef®cacy of
the anti-sense Sp1 vector to block Sp1 expression.
It should be noted that despite little Sp1 transcription factor,
clone B had growth capacities not discernible from that of clones
transfected with empty pRSV or that of parental NIH 3T3
®broblast cultures.
Two hypotheses may explain the variability in Sp1 DNA-
binding activity between clones A±E. First, establishment of stably
transfected clones was performed using cotransfection of two
plasmids, the ®rst bearing the anti-sense Sp1 construct, the other
bearing the selection gene (ampicillin). It cannot be excluded that
some of the clones do not carry the anti-sense vector but only carry
the ampicillin resistance gene. Secondly, it is likely that the pRSV/
ASSp1 copy number is not identical in the various clones, a factor
that may in¯uence Sp1 expression.
Effects of anti-sense Sp1 on ®broblast gene expression
pro®les as measured by cDNA microarray analysis The
technique of differential hybridization of Atlas cDNA expression
arrays was used to identify differences in the expression pattern of
853 known genes between empty pRSV-transfected clone 0 and
pRSV/ASSp1-transfected clone B. First, cDNA arrays containing
probe sets for 588 known mouse genes were used. Among these
genes, 266 of them did not show a signi®cant hybridization signal
in either pRSV- or pRSV/ASSp1-transfected clones (not shown).
Sixty-®ve cellular genes were inhibited by more than 50% by
pRSV/ASSp1 (Table I). This inhibitory effect was speci®c, as the
expression of 257 genes was not, or only slightly, modi®ed. None
of them were upregulated. Among the genes inhibited were several
whose products are involved in the cell cycle (cyclins D1, D2, D3,
cyclin-dependent kinase 5, for example). On the other hand,
several other genes from the same group were not affected (cyclin A,
cyclin B1, cyclin-dependent kinase 4). This selective effect of pRSV/
ASSp1 on cell-cycle-related genes may explain why the transfected
clones exhibit a normal growth behavior.
Next, to determine the effect of Sp1 gene targeting on ECM
gene expression, we used cDNA arrays containing probe sets for
265 known human ECM-related genes. This choice was driven by
the absence of commercially available mouse-speci®c arrays
containing suf®cient ECM-related gene probe sets. Signal/back-
ground ratios were optimized by testing various washing conditions
of the arrays after hybridizations (for details, see the corresponding
Materials and Methods section). Signi®cant expression levels were
noted for 111/265 genes. Among them, 43 were inhibited at least
2-fold in pRSV/ASSp1-transfected clone B (Table II). Select
hybridization results are presented in Fig 2(A), illustrating the
simultaneous reduction of steady-state mRNA levels for several
ECM-related genes: collagens (COL1A2, COL3A1, COL5A2,
COL6A1, COL6A2, COL6A3, COL8A1, and COL11A2),
proteoglycans (decorin, biglycan, versican), matrix metalloproteinases
(MMP-2, MMP-14, MMP-16, MMP-17, and MMP-19), ®bronec-
tin, integrin a8, and TIMP-1. At the mean time, 68 genes,
including those for TIMP-3, integrin a7, and emmprin, for example
(Fig 2B), showed no or little alteration in their expression levels.
Anti-sense Sp1 reduces the activity of various ECM
promoter/CAT reporter gene constructs We next tried to
determine whether the simultaneous reduction of steady-state
mRNA levels for ECM-related genes by anti-sense Sp1 expression,
as observed using differential cDNA array hybridization, resulted
from transcriptional inhibition at the level of their promoter
regions. We focussed our attention on the 5¢ regulatory regions of
genes encoding ®brillar collagens (COL1A2, COL1A1, COL5A2,
and COL3A1), TIMP-1, decorin, and type VII collagen (COL7A1).
Decorin is a small proteoglycan thought to play a part in type I
collagen ®brillogenesis (reviewed in Kuc and Scott, 1997). Type
VII collagen, a basement membrane-associated collagen,
component of the anchoring ®brils, whose diffuse expression in
the dermis has been observed in the affected skin from patients with
systemic sclerosis and may contribute to its tightly bound and
indurated appearance (Rudnicka et al, 1994). As shown in
Table III, all constructs tested had their activity signi®cantly
reduced by cotransfected pRSV/ASSp1. These results indicate that
the broad inhibition of mRNA steady-state levels resulting from
inhibition of Sp1 expression occurs at the transcriptional level,
consistent with the role of Sp1 as a transcription factor.
Modulation of promoter activity by Sp1 levels is
proportional to the number of Sp1 binding sites
available First, 5¢-end deletion constructs of the human
COL1A2 promoter were tested for their responsiveness to anti-
Figure 1. Stable expression of an anti-sense Sp1 vector ef®ciently
reduces Sp1 DNA-binding activity in NIH-3T3 ®broblasts. (A)
Nuclear extracts were prepared from clones of NIH 3T3 stably
transfected with either empty pRSV (clone 0, lane 1) or pRSV/ASSp1
(clones A±E, lanes 2±6). Sp1 DNA-binding activity was determined by
electrophoresis mobility shift assay, using a radiolabeled consensus Sp1
oligonucleotide. Note that protein/DNA complex formation is
dramatically reduced in lane 3 (clone B). (B) Supershift assays using
nuclear extracts from either clone 0 (lanes 1 and 2) or clone B (lanes 3
and 4) were carried out as described in the Materials and Methods section.
(C) Western blot analysis of Sp1 content in clone 0 (lanes 1 and 2) and
clone B (lanes 3 and 4), using either 20 mg (lanes 1 and 3) or 60 mg (lanes
2 and 4) of whole cell extracts.
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sense Sp1 expression. As shown in Fig 3, these constructs exhibit
various degrees of basal activity, consistent with previous
observations, and attributed to the presence of several functional
Sp1 sites (Inagaki et al, 1994; Chung et al, 1996; Ihn et al, 1996;
Higashi et al, 1998; Kouba et al, 1999). In particular, integrity of
the Sp1 sites located within the region ±342/±271 of the human
COL1A2 promoter is critical for maintenance of high promoter
activity (Inagaki et al, 1994; Chung et al, 1996; Ihn et al, 1996). An
80% inhibition of the activity of the longest construct,
±3500COL1A2/CAT, was observed. The extent of inhibition
was reduced to about 50% for constructs ±376 and ±342, and
dropped to about 30% for construct ±287. Shorter constructs, ±124
and ±108COL1A2/CAT, had little activity and were not inhibited
by the anti-sense Sp1 vector. A similar pattern of results was
observed using deletion constructs of the promoters for decorin,
COL3A1 and COL7A1, and TIMP-1 instead of those for
COL1A2 (not shown). Together, these results indicate that the
extent of inhibitory activity of pRSV/ASSp1 on a given promoter
is directly proportional to the number of functional Sp1-binding
sites.
Mammalian cells contain high levels of Sp1 and related
transcription factors that contribute to the basal expression of the
various genes identi®ed above. We decided to use Drosophila
melanogaster SL2 cells, the only higher eukaryotic cells known to be
devoid of endogenous Sp1 (Courey and Tjian, 1988), to further
characterize the part played by Sp1 cis-elements on the activity of
the various promoters studied above. Besides the lack of Sp1
protein, SL2 cells display a high degree of conservation of the
transcriptional machinery with mammalian cells, and permit
functional examination of transfected Sp1 (Hagen et al, 1994). In
fact, we and others have previously taken advantage of these unique
properties of SL2 cells to analyze Sp1 functions in the context of
various collagen promoters (Li et al, 1995; Vindevoghel et al, 1997;
Chen et al, 1998). First, SL2 cells were cotransfected with the same
5¢-end deletion constructs of the COL1A2 promoter linked to the
CAT gene described in Fig 3, together with an Sp1 expression
vector, pPacSp1 or its empty counterpart, pPac0. CAT activity was
measured 40 h later. As shown in Fig 4(A), all constructs exhibited
identical low basal activity in SL2 cells, a result that contrasts those
obtained in human dermal ®broblasts (see Fig 3) and consistent
with the absence of Sp1 in SL2 cells. Overexpression of Sp1
transactivated the constructs with increasing effectiveness as the
constructs extended 5¢ to include an increasing number of
functional Sp1 sites. These results are the reverse image of those
presented in Fig 3, and emphasize the critical role of the Sp1 cis-
elements described above. These data also indicate that unknown
upstream elements between nucleotides ±376 and ±3500 signi®-
cantly contribute to Sp1-driven COL1A2 expression, in addition
to the three characterized Sp1 sites between nucleotide positions ±
Table I. Genes inhibited at least 2-fold by pRSV/ASSp1 in
stably transfected NIH 3T3 ®broblasts, as measured using
differential hybridization of Atlas mouse cDNA arrays
(Clontech no. 7741-l)a
Accession no. De®nition
Oncogenes and tumor suppressors
X58876 p53-regulating protein
J04115 c-Jun proto-oncogene
MI 3071 A-Raf proto-oncogene
M64429 B-Raf proto-oncogene
M84607 platelet-derived growth factor a-receptor
U28495 Lfc proto-oncogene
U15784 She transforming adapter protein
D17584 b-protachykinin a
X67735 Mas proto-oncogene
Cell cycle regulators
S78355 cyclin Dl (GI/S-speci®c)
M83749 cyclin D2 (GI/S-speci®c)
U43844 cyclin D3 (GI/S-speci®c)
Z37110 cyclin G (G2/M-speci®c)
D29678 cyclin-dependent kinase 5
U10440 cdk inhibitor p27
U09507 cdk inhibitor p2l/Wa¯
Stress response proteins
D49482 0sp94 osmotic stress protein
J05186 ERp72endoplasmic reticulum stress protein
U41751 etoposide induced p53 responsive
(E124) mRNA
D78645 78 kDa glucose regulated protein
U40930 oxidative stress-induced protein mRNA
M10021 dioxin-inducible cytochrome P450
Hormone receptors
X13358 glucocorticoid receptor form A
M33324 growth hormone receptor
J05149 insulin receptor
Modulators, effectors, and intracellular transducers
M83336 interleukin-6 receptor b chain
S76657 cAMP response element binding protein I
U06922 Stat3
M61177 ERKI
L33768 Jak3 tyrosine-protein kinase
U03279 phosphatidylinositol 3-kinase catalytic subunit
U20238 GapIII; GTPase-activating protein
M21065 interferon regulatory factor 1
Apoptosis-associated proteins
MI6506 bcl2
D30687 glutathione S-transferase Pi 1
U19463 A20 zinc ®nger protein
U97076 FLIP-L; apoptosis inhibitor
L28177 gadd45
U04710 insulin-like growth factor receptor II
(IGFR II)
X57796 TNFR1 (55 kDa)
DNA synthesis, repair, and recombination proteins
X66323 ATP-dependent DNA helicase
II 86 kDa subunit
X96618 PA6 stromal protein
D64107 MmLiml5; RecA-like gene
Protein turnover
M14222 cathepsin B
X53337 cathepsin D
X06086 cathepsin 1
L28095 interleukin-converting enzyme
Transcription factors and DNA-binding proteins
26046 AT motif-binding factor ATBFI
M58566 butyrate response factor 1
L21671 epidermal growth factor receptor kinase
substrate EPS8
Z36885 Ets-related protein Sap IA
U20344 Gut-speci®c Kruppel-like factor GKLF
J03770 homeobox protein 4.2
U62522 Sp4 zinc ®nger transcription factor
U20532 nuclear factor related to P45 NF-E2
U09419 retinoid X receptor interacting protein
Table I (continued)
Accession no. De®nition
X70298 SRY-box containing gene 4
X91753 transcription factor SEF2
Growth factor and chemokine receptors
M28998 ®broblast growth factor receptor basic
Growth factors, cytokines, and chemokines
X69619 inhibin b A subunit
U44725 mast cell factor
L34169 thrombopoietin
M13177 TGF-bl
Cell surface antigens and adhesion proteins neurotransmitter receptors
M27129 CD44 antigen
X69902 integrin a6
aGenBank accession numbers, gene names and classi®cation as supplied by
Clontech.
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342 and ±271 (Inagaki et al, 1994; Tamaki et al, 1995; Chung et al,
1996).
Several 5¢-end deletion constructs of the COL3A1, decorin and
TIMP-1 genes were also tested for their responsiveness to
transfected Sp1 in SL2 cells. As shown in Fig 4(B±D), maximal
activation of the promoters was achieved with the largest
constructs, likely re¯ecting their higher content in Sp1 binding
sites as compared with the shorter constructs.
Decoy Sp1 oligonucleotides inhibit COL1A2 promoter
activity in vitro and in vivo As Sp1 is fundamental for the
high expression of several ECM-related genes, we wanted to
determine whether short oligonucleotides bearing a consensus Sp1-
binding sequence could be used as a decoy to decrease collagen
promoter activity. For this purpose, two approaches were used.
First, human dermal ®broblasts were transfected with the
±3500COL1A2/CAT construct, and various amounts of either
wild-type or mutant Sp1 double-stranded oligonucleotides were
added to the culture medium. Promoter activity was determined
24 h later. Results presented in Fig 5(A) indicate that Sp1
oligonucleotide, but not mSp1 in which the Sp1-binding site is
incapable of binding Sp1, as determined in electrophoresis mobility
shift assay experiments (not shown), ef®ciently decreased COL1A2
promoter activity in a concentration-dependent manner. Maximal
inhibition (55%) was observed with addition of 15 mg per plate of
Sp1 oligonucleotide. The COL7A1 promoter was equally inhibited
by Sp1 decoy oligonucleotides (not shown). No cellular toxicity
was observed with either oligonucleotide at any of the
concentrations tested.
Next, decoy Sp1 experiments were performed in a transgenic
mouse model in which 17 kb of the mouse COL1A2 promoter
drive the expression of the luciferase gene (Bou-Gharios et al,
1996). Speci®cally, 15 mg of either wild-type or mutant Sp1
oligonucleotides were injected intradermally to the back of 1 mo
old COL1A2/lux transgenic mice. Luciferase activity was deter-
mined 24 h later in the skin region surrounding the injections.
High levels of luciferase activity were found in control skin extracts
Figure 2. Select results from differential hybridizations of Atlas
human cell interaction cDNA expression arrays: effect of anti-
sense Sp1 expression. Differential hybridization of cDNA expression
arrays was performed as described in Materials and Methods. (A) NIH 3T3
®broblast genes inhibited at least 2-fold by stably transfected pRSV/
ASSp1. (B) Genes whose expression is not altered by the anti-sense.
Table II. ECM-related genes inhibited more than 2-fold by
pRSV/ASSp1 in stably transfected NIH 3T3 ®broblasts, as
measured using differential hybridization of Atlas human
cell interaction cDNA arrays (Clontech #7746-l)a
Accession no. De®nition
Cell±matrix interactions
X55525 collagen type I a-2
X14420 collagen type III pro-a-1
X15879 collagen type VI a-1
M34570 collagen type VI a-2
X52022 collagen type VI a-3
X57527 collagen type VIII a-1
X02761 ®bronectin
U16306 versican, isoforms VI, V2,V3
J04599 byglycan
M14219 decorin
L36531 integrin a8
J02703 integrin b3
J05633 integrin b5
J03210 MMP-2
D26512 MMP-14
D50477 MMP-16
X89576 MMP-17
X92521 MMP-19
X03124 TIMP-I
Cell±cell interactions
D12614 lymphotoxin (TNF-b)
L34060 cadherin-8
D13866 a-catenin
X87838 b-catenin
Y 11306 b-catenin/TCF-4
L40636 ephrin type-B receptor 1 precursor
L41939 ephrin type-B receptor 2 precursor
U07695 ephrin type-B receptor 4 precursor
M57730 ephrin-A1 precursor
M73980 Notch1
U77493 Notch2
U46461 dishevelled homolog
X97057 WNT-IOB
Cytoplasmic regulator and effectors
Z 18951 caveolin-1
U59752 cytohesin-1
LI1353 moesin-ezrin-radixin-like protein
Y07604 nucleoside diphosphate kinase
X17620 nucleoside diphosphate kinase A
U 11690 putative rho/rac guanine nucleotide exchange factor
M29870 RAS-related C3 botulinum toxin substrate I
(P21-RACI)
M64595 RAS-related C3 botulinum toxin substrate I
(P21-RAC2)
X69550 rho GDP-dissociation inhibitor 1
X06820 rhoB
L25080 proto-oncogene rhoA multidrug resistance protein
X94991 zyxin + zyxin-2
aGenbank accession numbers, gene names and classi®cation as supplied by
Clontech.
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(Fig 5B), consistent with previously published observations (Bou-
Gharios et al, 1996). The wild-type Sp1 oligonucleotide reduced
COL1A2 promoter activity by about 70%, whereas the mutant
oligonucleotide had no effect.
Collectively, these data suggest that decoy Sp1 oligonucleotides
diminish collagen promoter activity both in vitro and in vivo.
DISCUSSION
Using several complementary approaches, we have demonstrated
that Sp1 targeting may represent a powerful therapeutic approach
to reduce ECM accumulation in ®brotic conditions: (i) we have
shown that transcription factor Sp1 is critical for basal expression of
several ECM-related genes, and (ii) using two independent
experimental approaches to target Sp1, we have demonstrated
that interference with either the expression or the DNA-binding
activity of Sp1 results in transcriptional repression of several ECM
genes. First, selection of NIH-3T3 clones stably transfected with
pRSV/ASSp1 indicated that reduced Sp1 expression is compatible
with cell survival and growth and leads to simultaneous reduction
in the mRNA steady-state levels of numerous cellular genes,
including those encoding ®brillar collagens, proteoglycans and
other ECM-related proteins. This inhibition was the consequence
of reduced transcriptional activity, as measured using transient cell
transfections with several ECM-related promoter/reporter gene
constructs. Secondly, using decoy Sp1 oligonucleotides we have
demonstrated that interfering with Sp1 binding to its target
sequences, such as within the COL1A2 promoter, ef®ciently
blocks gene expression both in vitro and in vivo. These data were
obtained using either classic transient cell transfections of dermal
Figure 3. Inhibition of COL1A2 promoter activity by anti-sense
Sp1 correlates with the number of Sp1-binding sites. Fibroblasts in
late logarithmic growth phase were transfected with 5 mg of various 5¢
deletion constructs of the COL1A2/CAT promoter and 10 mg of either
empty pRSV (open bars) or pRSV/ASSp1 (solid bars). Forty hours later,
cell extracts were prepared and assayed for CAT activity. The relative
CAT activity (mean 6 SD) of three independent experiments performed
in duplicate is shown.
Figure 4. Contribution of Sp1 sites to
various ECM gene promoter transactivation.
Sp1-de®cient Drosophila SL2 cells were
cotransfected with different 5¢-end deletion
constructs of various ECM gene promoters linked
to the CAT gene, together with either empty
pPac0 (open bars) or pPacSp1 Sp1 expression
vector (solid bars). Forty hours after transfection,
cell extracts were assayed for CAT activity. The
relative promoter activities (mean 6 SD) from
three independent experiments performed in
duplicate is shown in the form of a bar graph.
The position of the 5¢-end of each construct is
indicated below each histogram bar. (A) COL1A2;
(B) COL3A1; (C) decorin; (D) TIMP-1.
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®broblasts in cultures or a transgenic mouse model that allows in vivo
monitoring of COL1A2 promoter activity (Bou-Gharios et al,
1996). In these animals, transcriptional decoy Sp1 oligonucleotide
competition ef®ciently decreased COL1A2 promoter activity at the
sites of injection in the skin.
Simultaneous monitoring of the expression of hundreds of
genes (863) using cDNA microarrays led us to the identi®cation
of numerous novel Sp1 targets (Tables I and II), Interestingly,
expression of the various cyclin genes was selectively inhibited,
a phenomenon that likely explains that pRSV/ASSp1 clones
had proliferation rates indiscernible from that of control clones.
The validity of our expression data was established by two
separate means. First, as stated above, a perfect correlation
between decreased mRNA steady-state levels and reduced
promoter activity for several ECM-related genes was observed.
Secondly, several of the genes that were identi®ed using cDNA
arrays has been shown previously to be under the transcriptional
control of Sp1. Notable among these genes are those encoding
transforming growth factor (TGF) -b1 (Geiser et al, 1993),
cyclin D1 (Kitazawa et al, 1999), or the cyclin-dependent kinase
inhibitors p21/Waf-1 (Moustakas and Kardassis, 1998) and p27
(Zhang and Lin, 1997).
Another interesting aspect of Sp1 targeting is that it may provide
the possibility to alter TGF-b-driven gene expression. TGF-b is the
prototypic ®brogenic cytokine, enhancing ECM gene expression
and downregulating that of matrix-degrading enzymes. Increased
expression of TGF-b is often associated with ®brotic states and
abnormal accumulation of ECM (review in Branton and Kopp,
1999). Initiation of cellular signaling of the TGF-b family of
growth occurs through speci®c serine/threonine kinase transmem-
brane receptors which, upon activation by TGF-b, phosphorylate
cytoplasmic mediators of the Smad family. The latter then
translocate into the nucleus where they act as transcription factors
(reviewed in Piek et al, 1999; MassagueÂ and Wotton, 2000). It has
been shown that Smad-mediated activation of the p15 and p21
gene by TGF-b requires direct Smad.Sp1 interactions (Feng et al,
2000; Pardali et al, 2000). Also, it has been proposed that Sp1 may
be necessary for TGF-b-driven activation of the human COL1A2
promoter (Greenwel et al, 1997), although 5¢ deletion studies
suggest the independence of TGF-b effects from Sp1 sites essential
for basal activity of the COL1A2 promoter (Chung et al, 1996).
Alteration of TGF-b signal by Sp1 targeting may also be obtained
by direct repression of the TGF-b1 gene whose activity is
in¯uenced by Sp1 cis-elements (Geiser et al, 1993). In this regard,
strong repression of TGF-b1 expression was also noted in our
experimental system using cDNA microarrays (see Table I).
Whether directly interfering with the Smad signaling cascade or
with TGF-b expression, Sp1 targeting may be useful to block the
®brogenic properties of TGF-b.
Pharmacologic targeting of Sp1 has been shown to inhibit
collagen gene expression. For example, mithramycin, a DNA-
intercalating tumor antibiotic with a high af®nity for GC-rich
sequences, speci®cally inhibits COL1A1 gene expression in
cultured ®broblasts by preventing Sp1, but not NF-1, binding
to its cognate cis-elements (Nehls et al, 1993). The use of this
drug for the treatment of ®brosis is likely impossible due to its
cellular and tissue toxicity and mutagenicity. It has been shown
to induce mutants in the phosphoribosyl-transferase locus and to
produce DNA strand breaks in vitro (Singh and Gupta, 1985).
Mithramycin is also known to induce hepatic and renal toxicity
associated with severe platelet dysfunction in patients under-
going tumor chemotherapy or treated for tumor-induced
hypercalcemia (reviewed in Weiss and Poster, 1982; Zojer
et al, 1999).
Together, our data indicate that repression of Sp1 expression
using anti-sense technology, and interference with Sp1 DNA-
binding activity using decoy experiments, represent ef®cient
approaches for a broad and simultaneous reduction of ECM-
related gene expression. These results suggest that Sp1 may be the
Figure 5. Decoy Sp1 oligonucleotides inhibit COL1A2 promoter
activity in vitro and in vivo. (A) Con¯uent human dermal ®broblast
cultures were transfected with 5 mg of ±3500COL1A2/CAT reporter
gene construct. After glycerol shock, increasing amounts (2, 5, and
10 mg) of Sp1 (open bars) or mSp1 (hatched bars) oligonucleotides were
added to the culture medium. Forty hours later, CAT activity was
determined and compared with that of cultures without oligonucleotides
(closed bar). Relative promoter activity (mean 6 SD) of three separate
experiments performed in duplicate is presented. (B) Four transgenic
mice carrying 17 kb of mouse COL1A2 promoter linked to the
luciferase gene in their genome were injected subcutaneously at distant
sites (approximately 2 cm apart) with 15 mg of either Sp1 (open bar) or
mSp1 (hatched bar) oligonucleotides in 25 ml of H2O. After a 30 h
incubation, animals were killed and luciferase activity was determined in
the skin surrounding the injection sites using identical amounts of
protein extracts (40 mg). A noninjected skin area was used as the control
(solid bar).
Table III. Anti-sense Sp1 expression vector inhibits the
activity of various ECM promoter/CAT reporter gene
constructsa
Promoter activitya
Promoter constructs
Co-transfected vector
% of inhibition
pRSV pRSV/ASSp1
±676COL1A1 32.9 6 5.7 15.1 6 1.1 54.1 6 3.3
±3500COL1A2 57.9 6 5.3 15.3 6 4.1 73.6 6 7.1
±400COL3A1 3.9 6 0.1 0.6 6 0.1 84.6 6 12.0
±2300COL5A2 4.3 6 0.6 2.9 6 0.4 32.5 6 9.3
±524COL7A1 6.1 6 0.3 4.7 6 0.2 22.9 6 3.3
±480decorin 15.1 6 0.8 3.5 6 1.5 76.8 6 9.9
±850TIMP-1 74.6 6 0.9 32.1 6 2.5 56.9 6 3.3
aCon¯uent human dermal ®broblast cultures were transfected with 5 mg of var-
ious ECM promoter/CAT reporter gene constructs, together with 10 ng of either
empty pRSV or pRSV/ASSp1. Forty hours after transfection, cell extracts were as-
sayed for CAT activity. Results presented as percent of acetylation are the
mean 6 SD of three independent experiments performed with duplicate samples.
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target of choice for the establishment of novel therapeutic
treatments of ®brotic states.
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